RxDoctor Payments Data

Gary Smith, MD

Family Medicine · Henderson, NCNPI 1528271848

Payments from drug & device makers

$14,113in general payments, 2019–2025

Across 716 payments — averaging $19.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
  • AstraZeneca$2K
  • GSK$1K
  • Pfizer$1K
  • Lilly USA, LLC$933
  • Esperion Therapeutics, Inc.$885
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$14,105100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,113 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$28,646
Medicare patients
148
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide145$233,816
EliquisApixaban108$98,932
RybelsusSemaglutide48$71,771
JardianceEmpagliflozin60$70,520
FarxigaDapagliflozin Propanediol55$51,942
JanuviaSitagliptin Phosphate53$48,472
XareltoRivaroxaban39$44,706
Tresiba Flextouch U-200Insulin Degludec32$41,264
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$27,430
TrulicityDulaglutide25$27,353
NexlizetBempedoic Acid/Ezetimibe37$26,204
MounjaroTirzepatide14$20,816
JanumetSitagliptin Phos/Metformin Hcl25$20,284
LinzessLinaclotide33$20,231
Breo ElliptaFluticasone/Vilanterol14$16,241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$3,703$305,587193 claims
PfizerEliquis$1,048$98,932108 claims
MerckJanuvia, Janumet, Belsomra$261$78,638101 claims
Boehringer IngelheimJardiance$364$70,52060 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,968$66,84068 claims
Lilly USA, LLCTrulicity, Mounjaro$933$48,16939 claims
Johnson & JohnsonXarelto$389$44,70639 claims
GSKTrelegy Ellipta, Breo Ellipta$1,102$43,67138 claims
Esperion Therapeutics, Inc.Nexlizet$885$26,20437 claims
AbbVieLinzess$353$20,23133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Henderson

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →